Virax Biolabs Group Ltd VRAX has launched the RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit in the European Union.
What Happened: The test kits are used at home and in point-of-care settings to accurately identify infections related to a respiratory syncytial virus (RSV), influenza, and COVID-19, with results typically available in 15 minutes.
The specialized diagnostic kits can be found by contacting the company's sales representatives.
The RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit is an in vitro immunochromatographic assay for the qualitative and differential detection of nucleocapsid protein antigen from influenza A, influenza B, RSV, and COVID-19 in nasal swab specimens from individuals with or without symptoms.
Why It Matters: Chairman & CEO James Foster commented, "the major industrialized economies are facing a triple threat this year through higher levels of RSV and influenza infections on top of the ongoing COVID-19 pandemic. Giving people the ability to test for all three at home will improve the ability of healthcare systems to manage these infections in a timely manner."
Price Action: VRAX shares are down 2.98% at $1.63 during the premarket session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.